Billiontoone (BLLN) reported $305M in revenue for fiscal 2025, +100.0% year on year. That ranks #2472 by revenue among 2853 SEC filers and #247 in Healthcare. Net income was $7.5M, a net margin of 2.4%. Revenue has grown 106.2% a year on average since 2023 ($71.7M then). The fiscal 2025 balance sheet shows $633M in total assets, $496M in cash and $57.2M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $305M | +100.0% | FY20252025-12-31 |
| Gross profitGrossProfit | $208M | +157.6% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $16.0M | +$63.2M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $7.5M | +$49.0M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $24.6M | +$66.0M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $8.9M | +64.4% | FY20252025-12-31 |
| Total assetsAssets | $633M | +109.4% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $480M | +$732M | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $496M | +159.0% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $57.2M | +11.2% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $108M | $18.0M | Open → |
| Q2 20262026-06-30 | $109M | $8.1M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Billiontoone, Inc.
- Ticker
- BLLN
- Exchange
- Nasdaq
- SIC classification
- Services-Medical Laboratories (8071)
- Fiscal year end
- 12-31
- CIK
- 0002070849
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KMar 11, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| AngiodynamicsANGO | $320M | −$36.7M |
| CormedixCRMD | $312M | $163M |
| Procept BioroboticsPRCT | $308M | −$95,572 |
| BilliontooneBLLN | $305M | $7.5M |
| Skinhealth SystemsSKIN | $301M | −$9.5M |
| EvolusEOLS | $297M | −$51.6M |
| Ironwood PharmaceuticalsIRWD | $296M | $24.0M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Billiontoone — Key figures |url=https://companiesranked.com/en/company/billiontoone |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Billiontoone — Key figures. CompaniesRanked. https://companiesranked.com/en/company/billiontooneBibTeX
@misc{companiesranked-en-company-billiontoone-2026,
author = {{CompaniesRanked}},
title = {{Billiontoone — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/billiontoone}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0002070849-26-000017 · March 11, 2026
{{cite web |title=Billiontoone — Key figures — 10-K (0002070849-26-000017) |url=https://www.sec.gov/Archives/edgar/data/2070849/000207084926000017/blln-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-11}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.